Skip to main content

Table 7 Background characteristics on patients harboring the T790M substitution through liquid biopsy (n = 58)

From: Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

Variable T790M mutation  
Positive
(n = 11)
Negative
(n = 47)
Total
Original mutation
 Absent 1 38 39
 Present 10 9 19
Bone metastases
 Absent 1 39 40
 Present 10 8 18
Enlargement of Tumor size
  <  12 mm 7 7 14
 12 mm ≤ 4 40 44
Brain metastases
 Absent 4 38 42
 Present 7 9 16
Detection of New tumor lesion
  <  4 4 38 42
 4 ≤ 7 9 16
Detection of New metastatic organ
 0 6 36 42
 1 2 7 9
 2 0 3 3
 3 1 1 2
 4 2 0 2
New minor site metastases
 Absent 8 45 53
 Present 3 2 5
Hepatic metastases
 Absent 8 44 52
 Present 3 3 6
Minor site metastases
 Absent 8 44 52
 Present 3 3 6
Mutation site at initial diagnosis
 Exon19 Deletion 4 41 45
 L858R 7 6 13
New hepatic metastases
 Absent 9 45 54
 Present 2 2 4
  1. Abbreviations: n number, minor site metastases; metastases of skin, kidney, ascites, lymphangiosis carcinomatosa, adrenal organ or others,